S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Buy THIS stock before Taiwan is attacked (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Laser breakthrough could send stock soaring 2,467% (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Laser breakthrough could send stock soaring 2,467% (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Buy THIS stock before Taiwan is attacked (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Laser breakthrough could send stock soaring 2,467% (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Laser breakthrough could send stock soaring 2,467% (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Buy THIS stock before Taiwan is attacked (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Laser breakthrough could send stock soaring 2,467% (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Laser breakthrough could send stock soaring 2,467% (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Buy THIS stock before Taiwan is attacked (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Laser breakthrough could send stock soaring 2,467% (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Laser breakthrough could send stock soaring 2,467% (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture

Inhibrx (INBX) Stock Price, News & Analysis

$38.28
-0.05 (-0.13%)
(As of 02/23/2024 ET)
Today's Range
$38.00
$38.56
50-Day Range
$27.89
$38.75
52-Week Range
$14.31
$39.50
Volume
441,718 shs
Average Volume
388,396 shs
Market Capitalization
$1.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.50

Inhibrx MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
4.6% Downside
$36.50 Price Target
Short Interest
Healthy
6.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.21
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.45) to ($4.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.57 out of 5 stars

Medical Sector

281st out of 943 stocks

Biological Products, Except Diagnostic Industry

39th out of 153 stocks


INBX stock logo

About Inhibrx Stock (NASDAQ:INBX)

Inhibrx, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has collaboration with 2seventy bio, Inc., Bristol-Myers Squibb Company, and Chiesi Farmaceutici S.p.A. The company was founded in 2010 and is headquartered in La Jolla, California.

INBX Stock Price History

INBX Stock News Headlines

The perfect AI stock under $10
Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion. However, new AI technology has the potential to make the process up to 1000 times faster. This #1 AI company is at the forefront of it all.
Inhibrx just downgraded at LifeSci Capital, here's why
Elon Musk's "Project Dojo" is a Game-Changer
Morgan Stanley predicts that Musk's latest act will boost Tesla's shares by 80% in the next 12 months. But if you want to profit from this development, you'll buy the firm that could see its sales explode by 829% as "Project Dojo" sweeps the nation.
Inhibrx Inc Ordinary Shares INBX
Inhibrx Inc Ordinary Shares
Inhibrx posts Q3 results
JMP Securities Reaffirms Their Buy Rating on Inhibrx (INBX)
See More Headlines
Receive INBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
2/24/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:INBX
Fax
N/A
Employees
132
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.50
High Stock Price Target
$46.00
Low Stock Price Target
$27.00
Potential Upside/Downside
-4.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-145,230,000.00
Net Margins
-42,880.00%
Pretax Margin
-42,878.64%

Debt

Sales & Book Value

Annual Sales
$2.19 million
Book Value
$1.33 per share

Miscellaneous

Free Float
36,792,000
Market Cap
$1.81 billion
Optionable
Optionable
Beta
3.03
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives















INBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Inhibrx stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INBX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INBX, but not buy additional shares or sell existing shares.
View INBX analyst ratings
or view top-rated stocks.

What is Inhibrx's stock price target for 2024?

3 analysts have issued 1-year target prices for Inhibrx's shares. Their INBX share price targets range from $27.00 to $46.00. On average, they expect the company's share price to reach $36.50 in the next year. This suggests that the stock has a possible downside of 4.6%.
View analysts price targets for INBX
or view top-rated stocks among Wall Street analysts.

How have INBX shares performed in 2024?

Inhibrx's stock was trading at $38.00 on January 1st, 2024. Since then, INBX shares have increased by 0.7% and is now trading at $38.28.
View the best growth stocks for 2024 here
.

Are investors shorting Inhibrx?

Inhibrx saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 2,400,000 shares, a drop of 41.3% from the January 15th total of 4,090,000 shares. Based on an average daily trading volume, of 715,000 shares, the days-to-cover ratio is currently 3.4 days. Currently, 6.7% of the company's shares are short sold.
View Inhibrx's Short Interest
.

When is Inhibrx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our INBX earnings forecast
.

How were Inhibrx's earnings last quarter?

Inhibrx, Inc. (NASDAQ:INBX) posted its earnings results on Tuesday, November, 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.06. The firm had revenue of $2.53 million for the quarter, compared to the consensus estimate of $1 million. Inhibrx had a negative trailing twelve-month return on equity of 424.05% and a negative net margin of 42,880.00%.

What other stocks do shareholders of Inhibrx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU).

When did Inhibrx IPO?

(INBX) raised $102 million in an IPO on Wednesday, August 19th 2020. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are Inhibrx's major shareholders?

Inhibrx's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.96%), Vestal Point Capital LP (3.24%), Capital Research Global Investors (1.51%), PFM Health Sciences LP (1.14%), Russell Investments Group Ltd. (0.92%) and Northern Trust Corp (0.66%). Insiders that own company stock include Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe.
View institutional ownership trends
.

How do I buy shares of Inhibrx?

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INBX) was last updated on 2/24/2024 by MarketBeat.com Staff